Horizon2020
SC1 – Health, Demographic change and Wellbeing- opportunità per il tema Salute (2016-2017)

Caterina BUONOCORE -
NCP SC 1 , APRE
22 Settembre, 2015, Milano
Agenda

• H2020 opportunities for health research
• SC 1- health, demographic change and wellbeing 2016-2017
• Results for 2014 and 2015 for Italy
• Other strategic Initiatives (IMI 2, JPs, Eranets etc).
• SME Instrument in SC 1 (optional)
H2020/ The Three Pillars

- Excellent science
- Industrial leadership
- Societal challenges
HEALTH in H2020

• Calls 2016-2017 are opening soon. (mid October)

• Health is highly interdisciplinary/permeates the 3 H2020 pillars

• Not all research can FIT in the Societal Challenge 1/collaborative research
• Health solutions can imply different phases of research and innovation.
STRUCTURE OF THE PROGRAMME: WHERE HEALTH could fit?

Excellent Science
- European Research Council
  - Frontier research by the best individual teams
- Future and Emerging Technologies
  - Collaborative research to open new fields of innovation
- Marie Skłodowska Curie actions
  - Opportunities for training and career development
- Research infrastructures
  (including e-infrastructure)
  - Ensuring access to world-class facilities

Industrial Technologies
- Leadership in enabling industrial technologies
  - ICT, NANOTECHNOLOGIES materials, biotechnologies, manufacturing, space
- Access to risk finance
  - Leveraging private finance and venture capital for research and innovation
- Innovation in SMEs
  - Fostering all forms of innovation in all types of SMEs

Societal Challenges
- Health, demographic change and wellbeing
- Food security, sustainable agriculture, marine and maritime research & the bioeconomy
- Secure, clean and efficient energy
- Smart, green and integrated transport
- Climate action, resource efficiency and raw materials
- Inclusive, innovative and reflective societies
- Security society

LARGEST PUBLIC PROGRAMME FOR RESEARCH AND INNOVATION

70 BILLIONS

OPEN TO ALL COUNTRIES IN THE WORLD
STRUCTURE OF THE PROGRAMME: WHERE HEALTH could fit?

- ERC
- MSCA
- SC1, 2, 3, 7..
- SME Instrument
- NMP-b
- FET
- ICT
- Materials

- GROUP of Researchers/actors doing collaborative multidisciplinary research
- ONE or more SME developing solutions close to market
- INDIVIDUAL RESEARCHER doing High risk/frontier Research
- INDIVIDUAL RESEARCHER targeting dev. of research career and training
- GROUP of researchers/actors doing research on Key enabling Technologies
- GROUP of researchers/actors doing basic/visionary but feasible research on technological aspects
- SME developing solutions close to market

WHERE HEALTH could fit?
2° PILLAR

INDUSTRIAL LEADERSHIP
Industrial /technological research

**Excellent Science**
- European Research Council
  - Frontier research by the best individual teams
- Future and Emerging Technologies
  - Collaborative research to open new fields of innovation
- Marie Skłodowska Curie actions
  - Opportunities for training and career development
- Research infrastructures (including e-infrastructure)
  - Ensuring access to world-class facilities

**Industrial Technologies**
- Leadership in enabling and industrial technologies
  - ICT, nanotechnologies, materials, biotechnology, manufacturing, space
- Access to risk finance
  - Leveraging private finance and venture capital for research and innovation
- Innovation in SMEs
  - Fostering all forms of innovation in all types of SMEs

**Societal Challenges**
- Health, demographic change and wellbeing
- Food security, sustainable agriculture, marine and maritime research & the bioeconomy
- Secure, clean and efficient energy
- Smart, green and integrated transport
- Climate action, resource efficiency and raw materials
- Inclusive, innovative and reflective societies
- Security society

---

European Institute of Innovation and Technology (EIT)
Spreading Excellence and Widening Participation
Science with and for society
Joint Research Center (JRC)
Connections to health in Pillar II

Industrial Technologies
- **Leadership in enabling and industrial technologies**
  - ICT, nanotechnologies, materials, biotechnology, manufacturing, space
- **Access to risk finance**
  - Leveraging private finance and venture capital for research and innovation
- **Innovation in SMEs**
  - Fostering all forms of innovation in all types of SMEs

- ICT for health
- Nano for health
- Materials for health
- Red Biotech

ICT
Nano-technology
Materials
Biotech
Health issues in II PILLAR: NMP-B

**Excellent Science**
- European Research Council
  - Frontier research by the best individual teams
- Future and Emerging Technologies
  - Collaborative research to open new fields of innovation
- Marie Skłodowska-Curie actions
  - Opportunities for training and career development
- Research Infrastructures (including - infrastructure)
  - Ensuring access to world-class facilities

**Industrial Technologies**
- Leadership in enabling and industrial technologies
- ICT, Nanotechnologies, materials, biotechnology, manufacturing, space
- Access to risk finance
  - Leveraging private finance and venture capital for research and innovation
- Innovation in SMEs
  - Fostering all forms of innovation in all types of SMEs

**Societal Challenges**
- Health, demographic change and wellbeing
- Food security, sustainable agriculture, marine and maritime research & the bioeconomy
- Secure, clean and efficient energy
- Smart, green and integrated transport
- Climate action, resource efficiency and raw materials
- Inclusive, innovative and reflective societies
- Security society

**Example**

**BIOTECHNOLOGY**
*From topics BIOTEC 01 to 08*

**ADVANCED MATERIALS AND NANOTECHNOLOGIES FOR HEALTHCARE**
*From topics NMBP 09 to 16*
3° PILLAR

SOCIETAL CHALLENGES
### PILLAR III: Societal Challenge

#### Excellent Science
- **European Research Council**
  - Frontier research by the best individual teams
- **Future and Emerging Technologies**
  - Collaborative research to open new fields of innovation
- **Marie Skłodowska Curie actions**
  - Opportunities for training and career development
- **Research infrastructures**
  - Including e-infrastructure
  - Ensuring access to world-class facilities

#### Industrial Technologies
- **Leadership in enabling and industrial technologies**
  - ICT, nanotechnologies, materials, biotechnology, manufacturing, space
- **Access to risk finance**
  - Leveraging private finance and venture capital for research and innovation
- **Innovation in SMEs**
  - Fostering all forms of innovation in all types of SMEs

#### Societal Challenges
- **Health, demographic change and wellbeing**
- **Food security, sustainable agriculture, marine and maritime research & the bioeconomy**
- **Secure, clean and efficient energy**
- **Smart, green and integrated transport**
- **Climate action, resource efficiency and raw materials**
- **Inclusive, innovative and reflective societies**
- **Security society**
HEALTH implications in Societal Challenges

- Health, demographic change and wellbeing
- Food security, sustainable agriculture, marine and maritime research & the bioeconomy
- Secure, clean and efficient energy
- Smart, green and integrated transport
- Climate action, resource efficiency and raw materials
- Inclusive, innovative and reflective societies
- Security society
Societal Challenge 2 - Food...

Excellent Science
- European Research Council
- Frontier research by the best individual teams
- Future and Emerging Technologies
  - Collaborative research to open new fields of innovation
- Marie Skłodowska Curie actions
  - Opportunities for training and career development
- Research infrastructures (including e-infrastructure)
  - Ensuring access to world-class facilities

Industrial Technologies
- Leadership in enabling and industrial technologies
  - ICT, Nanotechnologies, materials, biotechnology, manufacturing, space
- Access to risk finance
  - Leveraging private finance and venture capital for research and innovation
- Innovation in SMEs
  - Fostering all forms of innovation in all types of SMEs

Societal Challenges
- Health, demographic change and wellbeing
- Food security, sustainable agriculture, marine and maritime research & the bioeconomy
- Secure, clean and efficient energy
- Smart, green and integrated transport
- Climate action, resource efficiency and raw materials
- Inclusive, innovative and reflective societies
- Security society

Examples

Healthy and safe foods and diets for all
SFS-37-2016: The impact of consumer practices in food safety: risks and mitigation strategies
SFS-38-2016: Impulsivity and compulsivity and the link with nutrition, lifestyle and the socio-economic environment

Linking healthy oceans and seas for healthy people
BG-06-2017: Interaction between people, oceans and seas: a strategic approach towards healthcare and well-being
BG-07-2017: Blue green innovation for clean coasts and seas.
BG-08-2017: Innovative sustainable solutions for improving the safety and dietary properties of seafood
Societal Challenge 7- Security

Excellent Science
- European Research Council
- Future and Emerging Technologies
- Marie Skłodowska Curie actions
- Research infrastructures

Industrial Technologies
- Leadership in enabling and industrial technologies
- Access to risk finance
- Innovation in SMEs

Societal Challenges
- Health, demographic change and wellbeing
- Secure, clean and efficient energy
- Smart, green and integrated transport
- Climate action, resource efficiency and raw materials
- Inclusive, innovative and reflective societies

Examples

CIP - CfP 1 – 2016 AND 2017: Prevention, detection, response and mitigation of the combination of physical and threats to the critical infrastructure of Europe.
Scope: proposals should focus on one of the following critical infrastructures: water system, energy infrastructure, transport infrastructure, health services, and financial services.

SEC – DRS 1 -2016: Integrated tools for response planning and scenario building
Scope: disaster risks (natural, accidental, or intentional) should be addressed in the context of:
- The EU Civil Protection Mechanism (Decision 1313/2013), which paves the way for reinforced cooperation in civil protection assistance interventions for the protection primarily of people, and also of the environment and property in the event of natural and man-made disasters, emergency situations in case of mass events, acts of terrorism and technological, chemical, Biological, radiological or environmental accidents

SEC - DRS 3 -2016: Validation of biological toxins measurements after an incident: Development of tools and procedures for quality control
Scope: By their characteristics, biological toxins are in between the classical chemical and biological toxins, and are covered both by the Chemical Weapons Conventions (CWC) and Biological Weapons Convention (BWC). The large variability among families of biological toxins complicates their measurement and unambiguous identification in human specimens, and environmental or food samples. Toxins are rapidly metabolized and degraded after incorporation, limiting the time window for successful identification and forensic analysis. Proposal should develop quality control tools, as well as the Standard Operating Procedures necessary for establishing a mechanism to systematically validate laboratory-based measurement techniques, including sample preparation strategies and analyses made in-situ issued by mobile and quickly deployable laboratories, which should be proposed for adoption at EU level.
## H2020 Work Programmes: Multi-annual Programming

<table>
<thead>
<tr>
<th>Year</th>
<th>Strategic Programme</th>
<th>Work Programme 1</th>
<th>Strategic Programme</th>
<th>Work Programme 2</th>
<th>Strategic Programme</th>
<th>Work Programme 3</th>
<th>Work Programme 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2019</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Strategic Programmes:** short documents outlining priorities over 3 years, updated every two years.

**Work Programmes:** mirror the strategic programme and are updated over the same 2-year cycle.

- Smaller and continuous updates to respond to unexpected developments.

- Calls published on basis of WP.
- Ad hoc financing decision.
- Calls published on basis of WP.
- Ad hoc financing decision.
- Calls published on basis of WP.
- Ad hoc financing decision.
- Calls published on basis of WP.
Research and innovation – a growing priority for the EU
*Horizon 2020 must deliver*

- You should perform **EXCELLENT** research and innovation
- Your project must have an **IMPACT**
- Show **ADDED VALUE**, be multidisciplinary and well-implemented

Reflected in the evaluation criteria
Personalised Medicine: a novel approach with many challenges along the way

- R&D the basics
  - “Omics” Technologies
  - Data
  - Samples
  - Statistics
- R&D stratifying tools
  - Biomarkers Identification
  - Qualification Validation
  - Data modelling tools
  - Technical aspects & challenges
- R&D test in human
  - Clinical trials Methodologies
  - Ethics
  - Patient recruitment
- Towards the market
  - Diagnostics & Therapies
  - Approval processes
  - Regulatory aspects
- Uptake in healthcare
  - Pricing & Reimbursement
  - Health economy
  - HTA
  - Novel models of healthcare organisation
- In patients
  - Availability & usability in the clinic
  - Patient perspective
  - Equal treatment
  - Training of professionals

Prediction - Prevention – Treatment - Cure
Personalised Medicine
Workshops & conference

- Vision for Europe 2020: identify bottlenecks for PM implementation into clinical practise

- 2010: Preparatory workshops (-omics, biomarkers, clinical trials/regulatory, uptake)

- 2011: European Perspectives in PM conference

Available on: http://ec.europa.eu/research/health
Personalised medicine – towards a definition

"Personalised medicine refers to a medical model using molecular profiling for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention"
The SC1 Work Programme 2016-17 in brief

**Call 'Personalised Medicine'**

**Including 'coordination activities'**

**SME Instrument**: 2 Topics

**Other Actions**: 12 items (incl. InnovFin ID & "Birth Day Prize")

**Focus Area Digital Security**: 1 Topic

**Focus Area Internet of Things**: 1 Topic

€ 935 million
Budgetary context for H2020 SC1 in 2016-2017

- Horizon 2020 to contribute with € ~2.7 billion to EFSI plan
- Indicative budget figures adapted for SC1:
  - About €122 million (2016) & €112 million (2017) - CNECT budget line
- Consequences for SC1:
  - More limited number of actions compared to SC1 WP 2014-2015, also considering the oversubscription to SC1 WP 2014-2015
Main research priorities for 2016-2017

- Personalised medicine

- Promoting healthy ageing

- Human biomonitoring

- Health ICT

- Infectious Diseases

- InnovFin

- Maternal and child health
**What’s next?  WP 2016-2017**

### 1.1 Understanding health, well-being and disease

- **SC1-PM-01-2016:** Multi omics for personalized therapies addressing diseases of the immune system.
- **SC1-PM-02-2017:** New concepts in patient stratification.
- **SC1-PM-03–2017:** Diagnostic characterization of rare diseases.
- **SC1-PM-04–2016:** Networking and optimizing the use of population and patient cohorts at EU level.

### 1.2 Preventing disease

- **SC1-PM-05–2016:** The European Human Bio monitoring Initiative.
- **SC1-PM-06–2016:** Vaccine development for malaria and/or neglected infectious diseases.
- **SC1-PM-07–2017:** Promoting mental health and well-being in the young.

### 1.3 Treating and managing disease

- **SC1-PM-08–2017:** New therapies for rare diseases.
- **SC1-PM-09–2016:** New therapies for chronic diseases.
- **SC1-PM-10–2017:** Comparing the effectiveness of existing healthcare interventions in the adult population.
- **SC1-PM-11–2016-2017:** Clinical research on regenerative medicine.
**What’s next? WP 2016-2017**

1.4. Active ageing and self-management of health

SC1-PM-12–2016: PCP - eHealth innovation in empowering the patient
SC1-PM-13–2016: PPI for deployment and scaling up of ICT solutions for active and healthy ageing
SC1-PM-14–2016: EU-Japan cooperation on Novel ICT Robotics based solutions for active and healthy ageing at home or in care facilities
SC1-PM-15-2017: Personalised coaching for well-being and care of people as they age

1.5. Methods and data

SC1-PM-16–2017: In-silico trials for developing and assessing biomedical products
SC1-PM-17–2017: Personalized computer models and in-silico systems for well-being
SC1-PM-18–2016: Big Data supporting Public Health policies
SC1-PM-19–2017: PPI for uptake of standards for the exchange of digitalized healthcare records
SC1-PM-20-2017: Development of new methods and measures for improved economic evaluation and efficiency measures in the health sector

1.6. Health care provision and integrated care

SC1-PM-21-2016: Implementation research for scaling-up of evidence based innovations and good practice in Europe and low- and middle-income countries
What’s next? WP 2016-2017

Coordination activities

SC1-HCO-01-2016: Valorization of FP7 Health and H2020 SC1 research results
SC1-HCO-02-2016: Standardization of pre-analytical and analytical procedures for in vitro diagnostics in personalized medicine
SC1-HCO-03–2017: Implementing the Strategic Research Agenda on Personalized Medicine
SC1-HCO-04–2016: Towards globalization of the Joint Programming Initiative on Antimicrobial resistance
SC1-HCO-05–2016: Coordinating personalized medicine research
SC1-HCO-06–2016: Towards an ERA-NET for building sustainable and resilient health system models
SC1-HCO-07–2017: Global Alliance for Chronic Diseases (GACD)
SC1-HCO-08–2017: Actions to bridge the divide in European health research and innovation
SC1-HCO-09–2016: EU m-Health hub including evidence for the integration of mHealth in the healthcare systems
SC1-HCO-10–2016: Support for Europe’s leading Health ICT SMEs
SC1-HCO-11–2016: Coordinated action to support the recognition of Silver Economy opportunities arising from demographic change
SC1-HCO-12–2016: Digital health literacy
SC1-HCO-13-2016: Healthcare Workforce IT skills
SC1-HCO-14–2016: EU-US interoperability roadmap
SC1-HCO-15-2016: EU eHealth Interoperability conformity assessment
SC1-HCO-16-2016: Standardization needs in the field of ICT for Active and Healthy Ageing
European human biomonitoring initiative

**Strategic planning & coordination of national initiatives**

- Creating a European joint programme for monitoring and scientific assessment of human exposures to chemicals and potential health impacts
- Coordinating HBM initiatives in Europe at national and EU level with special focus on a two way dialogue between policy and science in support of evidence based policy making
- Implementation through a Joint Programme Co-Fund

**Implementation in SC1 Work Programme 2016-2017**

**Preventing diseases**
SC1-PM-05–2016: The European Human Biomonitoring Initiative
Infectious diseases

Implementation in SC1 Work Programme 2016-2017

- **Collaborative research** – HIV/AIDS, Malaria and Tuberculosis; Neglected Infectious Diseases (NID); Emerging Epidemics; Antimicrobial drug resistance (AMR)

- **New financial instruments** - InnovFin Infectious Diseases – joint initiative between EC-EIB

- **Inducement prizes** – Horizon 2020 prize for better use of antibiotics

- **Global initiatives** - Global Research Collaboration for Infectious Disease Preparedness (GLOPID-R); Global Tuberculosis Vaccine Partnership (GTBVP)

- **Public–private partnerships** – IMI2

- **Public–public partnerships** – EDCTP2

- **Joint Programming Initiative on AMR** – JPIAMR – ERA-INFECT
Understanding health, well-being and diseases
- SC1-PM-02-2017: New concepts in patient stratification
- SC1-PM-04-2016: Networking and optimising the use of population and patient cohorts at EU level

Preventing diseases
- SC1-PM-06-2016: Vaccine development for malaria and/or neglected infectious diseases

Treating and managing diseases
- SC1-PM-09-2016: New therapies for chronic diseases
- SC1-PM-10-2017: Comparing the effectiveness of existing healthcare interventions in the adult population

Coordination activities
- SC1-HCO-04-2016: Towards globalisation of the Joint Programming Initiative on Antimicrobial Resistance
Other Actions: InnovFin Infectious Diseases (InnovFin ID) Pilot

A New Financial Instrument for Infectious Diseases R&D:
- Jointly developed by the European Commission and European Investment Bank
- Launched on 15 June 2015 in Riga during 'The First Innovative Enterprise Week'
- Established under InnovFin - EU Finance for Innovators
- Provides loans between EUR 7.5m and EUR 75m to innovative players active in developing vaccines, drugs, medical and diagnostic devices, and research infrastructures for combatting infectious diseases

http://www.eib.org/innovfin
**Maternal and child health**

- Approximately 300,000 women died from preventable causes related to pregnancy and childbirth in 2013.
- Maternal and perinatal conditions are the seventh contributors to the global burden of disease.

**Other Actions: Horizon Prize on reducing maternal and newborn morbidity and mortality – the Birth Day Prize**

- The prize calls for a novel solution to improve the outcome of facility-based deliveries (of a clinical, technological or managerial nature, or a combination of these).
- Developed by European Commission and Bill & Melinda Gates Foundation.
- More details and prize launch at the high-level conference "Together for the next generation" on 8 December in Brussels.
Promoting healthy ageing

Health ICT

A large number of research and innovation topics, and coordination topics in the SC1 Work Programme 2016 - 2017
Other coordination activities

- SC1-HCO-01-2016: Valorisation of FP7 Health and H2020 SC1 research results

- SC1-HCO-07–2017: Global Alliance for Chronic Diseases (GACD)

- SC1-HCO-08–2017: Actions to bridge the divide in European health research and innovation
SME instrument in SC1 work programme 2016-2017

- SMEInst-05-2016-2017 – Supporting innovative SMEs in the healthcare biotechnology sector
- SMEInst-06-2016-2017 – Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well
• More strategic patient-centred approach and health promotion

• Creating a body of evidence for IT technologies, support for SME's growth, IT skills for healthcare workforce

• New approaches in managing health, from well-being to personalisation

• Data and sharing data challenges

• Decrease of time to market, better adaptation to innovation and support to policy

• Contribution to WHO activities and US cooperation

The entire chain of innovation is needed, from research to support actions and specific instruments.
ICT solutions for Active and Healthy Ageing:

- Exploring new opportunities
- Catalyse Silver Economy
- IoT for Smart Living Environments (with ICT-LEIT)
- Scale up Innovative Care Services
- Complementing previous calls
CSA EU mHealth Hub; CSA Digital Health literacy and IT skills health workforce; CSA Support for Health IT SMEs; CSA EU/US Interoperability roadmap support; CSA Interoperability conformity assessment

Uptake of standards (PPI);
Empowered hospitalised patient (PCP)

Support for eHealth related European SMEs (SME Instrument);
Clinical validation of VPH solutions (SME Instrument)

Simulation /modelling on wellbeing (RIA); In silico trials (RIA);
Big Data (RIA); Digital Security (RIA)
Understanding the call topics: example

- 'PHC 2 – 2015'
- 'Specific challenge'
  sets the context, the problem to be addressed, why intervention is necessary
- 'Scope'
  delineates the problem, specifies the focus and the boundaries of the potential action BUT without describing specific approaches
- 'Expected impact'
  describe the key elements of what is expected to be achieved in relation to the specific challenge
- 'Type of action'
Calendar for Horizon 2020
Work Programme 2016-2017
(indicative)

• 18 September 2015: SC1 Info Day – Brussels
• 13 October 2015: adoption of WP 2016-2017 by the Commission
• 14 October 2015: publication of WP 2016-2017
• Call 2016 deadlines (depending on topics): 19 January 2016 – 16 February 2016 and 13 April 2016
Multi-lateral health research activities

IRDiRC
www.irdirc.org/

IHEC
http://ihec-epigenomes.org/

GloPID-R
Global Research Collaboration for Infectious Disease Preparedness
http://www.glopid-r.org/

InTBIR
http://intbir.nih.gov/

International Cancer Genome Consortium
https://icgc.org/

Global Genomic Medicine Collaborative

GACD
www.gacd.org/
Translation into calls 2016-2017

• International Co-operations with Japan and US.

• ICT for health and ageing
  – Personalised in silico medicine and modelling technologies. Integrating heterogeneous sources of data.
SC1 and international cooperation

- Reference to specific multi-lateral initiatives
- Mutual opening of research programmes with Third Countries (US)
- Funding of Third Countries entities by their own funding agencies for participating to Horizon 2020 (Switzerland, Australia)
Template for clinical studies in SC1 (I)

Purpose

• Providing structured information to experts for evaluation

• Giving applicants the chance to provide detailed information about clinical studies without page limitations
  Reasons:
  ✓ Detailed but important information, e.g. about Scientific Advice Meetings, in-/exclusion-criteria, etc.
  ✓ Potentially high number of studies

• Providing necessary information to request 'unit costs'

• Available under 'call documents'¹ and in submission system

Scope

• Essential information – based on a generic Clinical Study Protocol

• When information is currently not available (e.g. a clinical study is planned for a later stage of the project and will be based on data of previous studies) the source of required data should be provided and / or the selection of the applied methodology should be described

• Each section must be shortly and concisely described. In case one or more issues do not apply to a particular study, please briefly explain/justify
Mandatory deliverables

1. 'First study subject approvals package',
   - Final version of the study protocol
   - Registration number of clinical study
   - Regulatory and/or ethics approvals

2. 'All approvals package', all further approvals

3. 'Midterm recruitment report', 50% recruitment

4. Report on status of posting results in the study registry(s), result posting
<table>
<thead>
<tr>
<th>ERA-Nets finanziati in Horizon 2020 (bandi 2014)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>E-Rare-3</strong></td>
</tr>
<tr>
<td>ERA-NET rare disease research implementing IRDiRC objectives</td>
</tr>
<tr>
<td><strong>ERACoSysMed</strong></td>
</tr>
<tr>
<td>ERACoSysMed - Collaboration on systems medicine funding to promote the implementation of systems biology approaches in clinical research and medical practice</td>
</tr>
<tr>
<td><strong>JPco-fuND</strong></td>
</tr>
<tr>
<td>ERA-NET for establishing synergies between the Joint Programming on Neurodegenerative Diseases Research and Horizon 2020</td>
</tr>
<tr>
<td><strong>TRANSCAN-2</strong></td>
</tr>
<tr>
<td>ERA-NET: Aligning national/regional translational cancer research programmes and activities</td>
</tr>
</tbody>
</table>
### ERA-Nets finanziate in Horizon 2020 (bandi 2015)

<table>
<thead>
<tr>
<th>ERA-CVD</th>
<th>ERA-NET on <strong>cardiovascular diseases</strong> to implement joint transnational research projects and set up international cooperations</th>
<th>DEUTSCHES ZENTRUM FUER LUFT - UND RAUMFAHRT EV</th>
<th>DE</th>
</tr>
</thead>
<tbody>
<tr>
<td>JPI-EC-AMR</td>
<td>ERA-NET for establishing synergies between the Joint Programming Initiative on <strong>Antimicrobial Resistance</strong> Research and Horizon 2020</td>
<td>VETENSKAPSRADEN - SWEDISH RESEARCH COUNCIL</td>
<td>SE</td>
</tr>
<tr>
<td>NEURON Cofund</td>
<td>ERA NET NEURON in the area of <strong>brain-related diseases and disorders of the nervous system</strong></td>
<td>DEUTSCHES ZENTRUM FUER LUFT - UND RAUMFAHRT EV</td>
<td>DE</td>
</tr>
</tbody>
</table>
Strategic Initiatives around HEALTH

Innovative Medicines Initiative 2
www.imi.europa.eu

European Innovation Partnership on Active and Healthy Ageing
https://webgate.ec.europa.eu/eipaha

Active and Assisted Living 2
www.aal-europe.eu

European & Developing Countries Clinical Trials Partnership (EDCTP2)
www.edctp.org
ALTRE OPPORTUNITÀ DI FINANZIAMENTO NEL SETTORE DELLA SALUTE
The European Union and the pharmaceutical industry have joined forces to make drug R&D processes in Europe more innovative and efficient, enhance Europe’s competitiveness & address key societal challenges by forming the biggest PPP in Life Science.
A Typical IMI Consortium

Private Investment *in kind* (€ 1 billion)

EU Public Funding *cash* (€ 1 billion)
IMI2 Life Cycle

**Topic definition phase**

- Industry consortium

**Stage 1**

- Academic research teams
- Hospitals
- Mid-size enterprises
- Regulators
- SMEs
- Patients’ organisations

**Stage 2**

- Applicant consortium
  - Industry consortium

**Granting phase**

- Signature of Consortium Agreement and Grant Agreement

**Identification of topics and willingness to collaborate by EFPIA companies and associated partners**

**Submission of short proposals by applicant consortia & evaluation by independent experts**

**Preparation of full proposal & evaluation by independent experts/ethical panel**

**Call launch**

**Invitation to selected team to merge with industry team**

**Start of the Granting phase**

**Project launch!**
IMI accelerates the development of new therapies for major yet unmet public health needs and diseases where treatments are lacking
IMI portfolio – budget breakdown

- Drug Discovery: 14%
- Infectious Diseases: 16%
- Brain Disorders: 11%
- Metabolic Disorders: 9%
- Drug Safety: 9%
- Stem Cells: 8%
- Data Management: 6%
- Cancer: 5%
- Biologicals: 4%
- Others: 5%
How to apply: a 2-stage process

**Stage 1**

1. **Launch of the Call**
   - by IMI Executive Office

2. **Evaluation based on scientific excellence**
   - **Stage 1**
     - **Submission of Expressions of interest**
       - by Applicant Consortia (academics, SMEs, patients ...)
     - **1st peer review:**
       - **assessment**
       - **+ ranking**
       - by independent experts + EFPIA topics coordinators
     - **Approval of the 1st ranked consortia**
       - by IMI Governing Board
     - **Invitation to submit Full Project Proposal**
       - to first ranked Applicant Consortium + EFPIA Consortium

**Stage 2**

1. **Evaluation of feasibility and scientific excellence**
   - **Stage 2**
     - **Submission of Full Project Proposal**
       - best ranked Applicant Consortium + EFPIA Consortium
       - = Full Project Consortium
     - **Evaluation through 2nd peer review, including ethical evaluation**
       - by independent experts
     - **Approval of the projects**
       - by IMI Governing Board

~ 5 months

~ 4 months
Successful EoI Applicants

Unsuccessful EoI Applicants

- Albania (1, 0.0%)
- Austria (131, 18.3%)
- Belgium (237, 21.9%)
- Bosnia and Herzegovina (2, 0.0%)
- Bulgaria (10, 0.0%)
- Croatia (15, 13.3%)
- Cyprus (8, 12.5%)
- Czech Republic (48, 8.3%)
- Denmark (143, 24.5%)
- Estonia (20, 10.0%)
- Finland (103, 18.4%)
- Macedonia (1, 0.0%)
- France (504, 26.0%)
- Germany (785, 22.7%)
- Greece (104, 10.6%)
- Hungary (63, 12.7%)
- Iceland (14, 7.1%)
- Ireland (72, 13.8%)
- Israel (73, 17.8%)
- Italy (609, 10.0%)
- Kosovo (2, 0.0%)
- Latvia (9, 11.1%)
- Lithuania (9, 0.0%)
- Luxembourg (17, 47.1%)
- Malta (3, 0.0%)
- Moldova (Republic of) (2, 0.0%)
- Netherlands (414, 28.0%)
- Norway (49, 12.2%)
- Poland (74, 6.8%)
- Portugal (80, 6.3%)
- Romania (45, 2.2%)
- Serbia (11, 9.1%)
- Slovakia (14, 0.0%)
- Slovenia (17, 0.0%)
- Spain (605, 15.5%)
- Sweden (228, 27.6%)
- Switzerland (192, 25.5%)
- Turkey (10, 10.0%)
- Ukraine (1, 0.0%)
- United Kingdom (926, 26.6%)
## Top 20 Beneficiaries

<table>
<thead>
<tr>
<th>Organisation</th>
<th>Country</th>
<th>Projects</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Institut National de la Santé et de la Recherche Médicale</td>
<td>France</td>
<td>22</td>
<td>€71,031,446</td>
</tr>
<tr>
<td>London School of Hygiene and Tropical Medicine</td>
<td>United Kingdom</td>
<td>5</td>
<td>€59,419,008</td>
</tr>
<tr>
<td>Centre Hospitalier Universitaire de LIMOGES</td>
<td>France</td>
<td>3</td>
<td>€43,296,622</td>
</tr>
<tr>
<td>Uppsala Universitet</td>
<td>Sweden</td>
<td>9</td>
<td>€37,666,409</td>
</tr>
<tr>
<td>The Chancellor, Masters and Scholars of the University of Oxford</td>
<td>United Kingdom</td>
<td>17</td>
<td>€33,586,016</td>
</tr>
<tr>
<td>Universitair Medisch Centrum Utrecht</td>
<td>Netherlands</td>
<td>5</td>
<td>€33,543,912</td>
</tr>
<tr>
<td>University of Dundee</td>
<td>United Kingdom</td>
<td>6</td>
<td>€20,920,436</td>
</tr>
<tr>
<td>Karolinska Institutet</td>
<td>Sweden</td>
<td>16</td>
<td>€19,513,599</td>
</tr>
<tr>
<td>Pivot Park Screening Centre BV</td>
<td>Netherlands</td>
<td>1</td>
<td>€17,182,800</td>
</tr>
<tr>
<td>World Vision of Ireland</td>
<td>Ireland</td>
<td>1</td>
<td>€15,284,473</td>
</tr>
<tr>
<td>UNIVERSITEIT ANTWERPEN</td>
<td>Belgium</td>
<td>7</td>
<td>€15,119,479</td>
</tr>
<tr>
<td>Université de Genève</td>
<td>Switzerland</td>
<td>11</td>
<td>€13,046,442</td>
</tr>
<tr>
<td>The University of Edinburgh</td>
<td>United Kingdom</td>
<td>7</td>
<td>€13,013,811</td>
</tr>
<tr>
<td>King’s College London</td>
<td>United Kingdom</td>
<td>9</td>
<td>€12,306,705</td>
</tr>
<tr>
<td>Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.</td>
<td>Germany</td>
<td>7</td>
<td>€11,324,390</td>
</tr>
<tr>
<td>European Clinical Research Infrastructure Network</td>
<td>France</td>
<td>1</td>
<td>€11,311,611</td>
</tr>
<tr>
<td>Stichting VU-VUmc</td>
<td>Netherlands</td>
<td>13</td>
<td>€11,242,543</td>
</tr>
<tr>
<td>Bristol University</td>
<td>United Kingdom</td>
<td>2</td>
<td>€10,674,001</td>
</tr>
<tr>
<td>Imperial College London</td>
<td>United Kingdom</td>
<td>9</td>
<td>€10,365,553</td>
</tr>
</tbody>
</table>
IMI 2 - Call 5

Call topics

- **Patient perspective** elicitation on **benefits and risks of medicinal products**, from development through the entire life cycle, to inform the decision-making process by **regulators** and **health technology assessment** bodies.
- **Diabetic kidney disease** biomarkers (DKD-BM).
- **Inflammation and AD**: modulating microglia function – focussing on TREM2 and CD33.
- Understanding the role of **amyloid imaging** biomarkers in the current and future diagnosis and management of patients across the spectrum of **cognitive impairment** (from pre-dementia to dementia).
- Evolving models of **patient engagement** and access for earlier identification of **Alzheimer’s disease**: phased expansion study.
- From **ApoE biology** to validated **Alzheimer’s disease** targets.

Scadenza 1st stage:
13 Ottobre 2015
Future Topics

- **New!** Indicative topic texts added

The following topics are under consideration for inclusion in Calls for proposals to be launched in the early autumn.

Topics under the **Big Data for Better Outcomes** programme:

- Coordination and Support Action (CSA) for the **Big Data for Better Outcomes** programme
- Real world outcomes across the AD (Alzheimer’s disease) spectrum (ROADS) to better care
- Development of an outcomes-focused platform to empower policy makers and clinicians to optimize care for patients with **haematologic malignancies**

Other topics:

- Development of **quantitative system toxicology** (QST) approaches to improve the understanding of the **safety** of new medicines
- Establishing impact of **RSV (respiratory syncytial virus) infection**, resultant disease and public health approach to reducing the consequences
- Joint **influenza vaccine** effectiveness surveillance

### Tentative dates

<table>
<thead>
<tr>
<th>Call Identifier</th>
<th>CALL 6 - H2020-JTI-IMI2-2015-06</th>
<th>CALL 7 - H2020-JTI-IMI2-2015-07</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type of action</td>
<td>RIA - research and innovation action</td>
<td>Research and innovation action</td>
</tr>
<tr>
<td></td>
<td>CSA – coordination and support action</td>
<td></td>
</tr>
<tr>
<td>Publication Date</td>
<td>30 September 2015</td>
<td>16 September 2015</td>
</tr>
<tr>
<td>Stage 1 Submission start date</td>
<td>30 September 2015</td>
<td>16 September 2015</td>
</tr>
<tr>
<td>Stage 1 Submission deadline</td>
<td>12 January 2016</td>
<td>4 November 2015</td>
</tr>
<tr>
<td>Stage 2 Submission deadline</td>
<td>14 June 2016</td>
<td>1st February 2016</td>
</tr>
</tbody>
</table>
DG SANCO
Third Health Programme 2014-2020
Il programma si concentra su quattro obiettivi principali, il cui scopo è conseguire un forte potenziale di crescita economica grazie al miglior stato di salute:

1) Sviluppare strumenti e meccanismi comuni a livello dell'UE per affrontare la carenza di risorse umane e finanziarie, al fine di contribuire a sistemi sanitari innovativi e sostenibili;

2) Migliorare l'accesso alle competenze mediche e alle informazioni concernenti patologie specifiche anche su scala transnazionale e sviluppare soluzioni condivise e orientamenti per migliorare la qualità della sanità e della sicurezza dei pazienti.

3) Individuare, diffondere e promuovere l'adozione di buone pratiche convalidate per prevenire le malattie e promuovere la buona salute.

4) Sviluppare approcci comuni per proteggere i cittadini dalle minacce sanitarie transfrontaliere.

CHI NE BENEFICIERÀ E COME

➢ **Direttamente:** tutte le amministrazioni pubbliche nazionali ed europee attive nell'assistenza sanitaria, e gli organismi privati, le ONG e i gruppi di interesse che promuovono politiche e sistemi sanitari più adatti alle attuali sfide demografiche e sociali.

➢ **Indirettamente:** tutti gli europei, grazie a una migliore assistenza sanitaria, alla promozione della salute e a misure di prevenzione.

La partecipazione è aperta ad una vasta gamma di organizzazioni, tra cui:

- Gli Istituti di Ricerca, Università e Ospedali
- Gli enti pubblici
- ONG
- Imprese Commerciali

Le dotazioni finanziarie per l'attuazione del programma per il periodo dal 1° gennaio 2014 al 31 dicembre 2020 ammonteranno a **449,4 milioni di EUR.**
Come partecipare?

Vi interessa partecipare al programma per la salute? Tutte le informazioni, insieme al modulo di candidatura, sono disponibili qui: Agenzia Esecutiva per la Salute e i Consumatori - EAHC

Il referente nel nostro paese

Contattate il referente nel vostro paese per ottenere assistenza e consigli:

**Punto focale nazionale**
Dr Giovanni NICOLETTI
Ministero della Salute
nfp_eahc@sanita.it

Per ulteriori informazioni:
http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/hp/
Active & Healthy Ageing

A European Innovation Partnership
I settori d'intervento prioritari sono stati individuati nel piano strategico di attuazione e nel piano operativo, adottati nel 2011 dal gruppo direttivo incaricato dell'avvio e dell'attuazione della partnership.

Per realizzare il piano tutti i soggetti interessati hanno iniziato a collaborare nell'ambito di gruppi d'azione.

- **Action Group A1**: Prescription and adherence action at regional level.
- **Action Group A2**: Personalized health management: Falls prevention.
- **Action Group A3**: Prevention of functional decline and frailty.
- **Action Group B3**: Integrated care for chronic diseases, including remote monitoring at regional level.
- **Action Group C2**: Interoperable independent living solutions.
- **Action Group D4**: Age friendly buildings, cities and environments.

Stakeholders wishing to get involved in the advancing of Specific Actions have formed **Action Groups** through the "**Invitation for Commitment**" application process. In each Action Group, stakeholders **commit to running a number of activities, contributing towards the headline target, starting with the creation and implementation of an Action Plan.**
E' attivo online anche un "**Marketplace per idee innovative**", che rientra in EIP.

* E' uno spazio interattivo per scambiare opinioni, trovare partners o iniziative al fine di mettere in pratica delle idee innovative:
  
  https://webgate.ec.europa.eu/eipaha/

---

**Launch of the Convenant on Demographic Change and Innovation for age-friendly environments in Europe**, Brussels, 7 December 2015

---

**Per ulteriori Informazioni:**

http://ec.europa.eu/research/innovation-union/index_en.cfm?section=active-healthy-ageing
La strategia del JPND rappresenta una visione per coordinare la ricerca nell'ambito delle malattie neurodegenerative, in particolare l'Alzheimer. Si affronta l'intero spettro di attività di ricerca che è necessario per affrontare il peso crescente di queste patologie per il prossimo decennio e oltre.

L'obiettivo del Programma Congiunto (JPND)* è quello di migliorare rapidamente la nostra comprensione delle cause di questo tipo di malattie. Oltre a fornire ai medici gli strumenti per diagnosticare e trattare queste malattie sin dalla fase precoce, il JPND dovrebbe anche portare ad un migliore sistema di assistenza sanitaria e sociale sia per i pazienti che per chi si prende cura di loro.

*The JPND diseases are:
Alzheimer’s disease (AD) and other dementias, Parkinson’s disease (PD) and PD related disorders, Prion disease, Motor neurone diseases (MND), Huntington’s Disease (HD), Spinocerebellar ataxia (SCA), Spinal muscular atrophy (SMA)
**Implementation Plan**

A first-phase JPND Implementation Plan has been agreed for the **period of 2012-2014**. The plan has these major action areas:

**Annual Calls for Proposals**
- Action Groups to determine research needs and opportunities
- Action Groups to promote engagement, commitment and partnerships

**Annual Calls for Proposals**

JPND intends to launch Calls for proposals each year to address high priority areas in neurodegenerative disease research. Over the period of 2012-2014, it is anticipated that JPND will launch calls to address each of the following priority areas:

- **Next Call ???**

*In general: Minimum 3 and maximum of 6 research groups (principal investigators) from at least 3 different countries of the funding organizations participating in this call*

http://www.neurodegenerationresearch.eu/initiatives/annual-calls-for-proposals/open-calls/

**NEW Partnering Tool**

http://www.neurodegenerationresearch.eu/initiatives/annual-calls-for-proposals/partnering-tool/
Per ulteriori informazioni:

Adriana Maggi, Ph.D.
Member of the JPND Management Board
Director Center of Excellence on Neurodegenerative Diseases University of Milan
adriana.maggi@unimi.it

JPND website
http://www.neurodegenerationresearch.eu/home/

secretariat@jpnd.eu
SERVIZI A SUPPORTO DEL NETWORKING
E RICERCA DI NUOVI PARTNER
Welcome to HealthCompetence

This website includes all projects related to life science and health supported by the European Commission since 2004. It gives visibility to organisations and scientists involved in these projects and, together with interactive search devices, facilitates the identification of potential collaboration partners and the set up of partnerships between academia and industry in health research.

HealthCompetence will also progressively give access to the research results in terms of technology offers, patents and publications.

Simple Search
Project Search
Person Search
Generate your report

www.HealthCompetence.eu
An open, pan-European infrastructure for information on research projects & results within Health Science

Help & Support:
support@avedas.com

Online Survey:
Please take part in our survey
HealthCompetence Online Survey
A chi rivolgersi per un supporto?

**Participant portal:**

**Per progetti finanziati:**

- **Punti di Contatto Nazionali (APRE)**
  - Informazioni pratiche & consigli sulle procedure e regole di partecipazione

- **National delegates in Programme Committees**
  - Interpretazione scientifica dei bandi, input all’elaborazione dei Work Programme

- **European Enterprise Networks (EEN)**
- **EC Information desks** (contattabili via e-mail o telefono)
ARIaT – Horizon 2020 Annotated Research and Innovation Actions Template

Innovation dimension in Horizon 2020 proposals: set of good practices to understand and write innovation related issues both in Research and Innovation Actions (RIA) and Innovation Actions (IA)

http://health2market.eu/results/h2020-annotated-template

The annotated template aims to assist applicants to the Research and Innovation Actions (RIA) and Innovation Actions (IA) of Horizon 2020 Framework Programme for 2014-2020 to better understand the requirements of the templates and better write innovation-related issues in the H2020 proposals. It highlights and emphasise the innovation elements that an excellent project application should contain.

A successful project proposal needs to speak out convincingly to a broad readership encompassing experts from a wide range of fields. While the scientific/technical soundness of a proposal is central to its ultimate success, it is also essential that the challenges to be addressed, opportunities to be exploited, and results to be achieved are clear and understandable to all readers, specifically to Horizon 2020 evaluators. Moreover, the linkage between results to be achieved and their relevance for European policy orientations should be clear, as well as the economic opportunities they will provide for citizens. The ARiAT Template has been structured to guide project formulators in presenting information required especially by the criteria of Excellence (criterion 1) and Impact (criterion 2). The Appendices include an example of a business plan executive summary and an example of work packages addressing dissemination and exploitation of results, preparation of market authorisation and market access (related to health topic).

The document is edited by APRE (Italy), Horizon 2020 National Contact Point for Health – Societal Challenge 1, and co-authored by specialists from engage AG (Germany), inno TSD (France), IE Business School (Spain) and SKEMA Business School (France). It reflects the view of the authors, who are experts dealing with H2020 proposals, innovation, exploitation of R&D results, and generally with entrepreneurship and business development on day-to-day basis. Their recommendations are indicated in the document as “Expert recommendations” and also include feedback collected from evaluators of H2020 proposals and concrete examples.

http://health2market.eu/results/h2020-annotated-template
Support and help

• Participant Portal
  • http://ec.europa.eu/research/participants/portal/desktop/en/home.html

• ECAS account creation
  • https://webgate.ec.europa.eu/cas/eim/external/register.cgi

• FAQ
  • http://ec.europa.eu/research/participants/portal/desktop/en/support/faq.html

• FITFORHEALTH: ricerca partner
  • http://mm.fitforhealth.eu/common/contactslogin.asp

• HEALTH2MARKET: assistenza a portare i risultati della ricerca al mercato.
  • http://www.health2market.eu/
GRAZIE PER L’ATTENZIONE!

APRE
Agenzia per la Promozione della Ricerca Europea
via Cavour, 71
00184 - Roma
www.apre.it
Tel. (+39) 06-48939993
Fax. (+39) 06-48902550

Health NCP
buonocore@apre.it